Business context and reporting period
ImmuCell Corporation’s Form 10-K covers the fiscal year ended December 31, 2019. The animal-health company develops and sells products for dairy and beef cattle. Its First Defense product line prevents scours in newborn calves; its principal development program, Re-Tain, is a proposed treatment for subclinical mastitis in lactating cows.
Financial performance and position
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Product sales | $13.72 million | $10.99 million |
| Gross margin | $6.74 million; 49% of sales | $5.19 million; 47% of sales |
| Operating loss | $0.95 million | $1.45 million |
| Net loss | $1.30 million; $0.19 per share | $2.32 million; $0.42 per share |
| Cash from operations | $0.23 million | Cash used: $0.37 million |
Sales increased 25%, principally on First Defense growth. The company reported a 24% increase in First Defense sales; that line represented 97% of product sales in both years. Gross margin improved to 49%, though newer gel formats remain more costly to produce. Product-development expense rose to $3.69 million; reported losses included substantial non-cash depreciation, amortization and stock compensation.
At year-end, cash and cash equivalents were $6.29 million, short-term investments $2.48 million, net working capital $10.69 million, total assets $38.69 million and stockholders’ equity $28.99 million. Bank debt was approximately $8.52 million, with $1.27 million classified as current. Capital spending was $1.39 million. The company reported no cash dividends.
Material changes versus the prior period
- Annual sales rose $2.74 million, while net loss narrowed by approximately $1.03 million.
- Operating cash flow improved by about $0.61 million to positive $0.23 million.
- Cash, cash equivalents and short-term investments increased to $8.77 million from $2.52 million, helped by a March 2019 common-stock offering that generated $8.30 million net. Shares outstanding increased about 30% year over year.
- First Defense production constraints—particularly vaccine-yield difficulties affecting Tri-Shield—eased, enabling a return to broader distribution in the second half of 2019. Second-half sales rose 30% year over year.
- The company recorded a $0.70 million gain on an asset sale in 2018, with no comparable gain in 2019.
Outlook, commentary and risks
- Management stated that available liquidity and anticipated product margins should fund operations and capital needs for at least 12 months from the filing date. This is management’s assessment, not a revenue or earnings forecast.
- Management’s objectives include growing annual product sales from nearly $14 million toward approximately $20 million and, longer term, exceeding $30 million within five years after Re-Tain’s launch. These are targets, not guaranteed outcomes.
- Re-Tain had received four of five significant FDA technical-section approvals. The final Chemistry, Manufacturing and Controls work remained outstanding; management expected a further submission before year-end 2020 and described potential approval during 2021. FDA review, manufacturing readiness and inspections could delay or prevent approval. A 2019 FDA pre-approval inspection identified deficiencies, to which the company submitted responses.
- Planned investment included approximately $3.5 million to expand First Defense capacity, targeting annual production capacity of about $27 million, and approximately $4 million to bring Re-Tain formulation and aseptic filling in-house. The company expected the First Defense expansion to be completed around mid-2020 and the Re-Tain facility to operate in 2022.
- On March 11, 2020, after year-end, the company refinanced its bank debt with $8.6 million of fixed-rate notes at 3.50% and obtained a $1.0 million line of credit. The new debt requires $1.4 million in escrow and approximately $871,000 of principal and interest payments over its first 12 months. The refinancing reduced variable-rate exposure; the company reported covenant compliance at filing.
- Key risks include reliance on First Defense and a small number of distributors, manufacturing yields and capacity, dependence on third-party suppliers, Re-Tain regulatory and commercialization risk, debt service and funding needs, and volatility in dairy and beef economics. COVID-19 effects on supply, labor, demand and the broader economy were uncertain as of filing.
- The company recorded a full valuation allowance against net deferred tax assets; no deferred tax asset was recognized at year-end. The 2019 audit opinion was unqualified. Management said disclosure controls and internal control over financial reporting were effective, but the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Subsequent filings and results: whether First Defense expansion was completed on schedule and delivered the targeted capacity, yields and margins.
- Re-Tain milestones: timing and outcome of FDA submissions, inspections and approval, and whether commercial production and market demand support management’s targets.
- Liquidity and debt: the $1.4 million escrow restriction, scheduled payments, covenant compliance and use of the new line of credit.
- Commercial concentration: continued reliance on First Defense for 97% of sales and on two distributors for 69% of 2019 sales.
- COVID-19 and industry conditions: realized effects on manufacturing, supply availability, customer economics and product demand.